NCT04049760View on ClinicalTrials.gov

Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 11, 2019

Primary Completion Date

November 29, 2024

Study Completion Date

November 29, 2024

Conditions
Fabry Disease
Interventions
DRUG

migalastat HCl 150 mg

migalastat HCl 150 mg capsule

Trial Locations (6)

22030

Lysosomal & Rare Disorders Research & Treatment Center, Fairfax

30322

The Emory Clinic, Atlanta

33606

University of South Florida, Tampa

45229

Cincinnati Children's Hospital, Cincinnati

55454

University of Minnesota Masonic Children's Hospital and Clinics, Minneapolis

Unknown

Royal Free London NHS Foundation Trust, London

Sponsors
All Listed Sponsors
lead

Amicus Therapeutics

INDUSTRY